目的:本荟萃分析的目的是研究肺癌中三级淋巴细胞浸润的临床病理和预后意义。
方法:在许多数据库中进行了系统搜索,包括PubMed,WebofScience,科克伦图书馆,Embase,CNKI,Wangfangdate,和CBM,直到2024年1月。我们计算了危险比(HR),赔率比(OR),和置信区间(CI),并用Stata15软件完成了这项荟萃分析。
结果:14项研究,包括3101名患者,进行了分析。高TLS检测与较长的OS相关(HR=0.545,95%CI:0.359-0.827,p=0.004),DFS(HR=0.431,95%CI:0.350-0.531,p<0.001),和RFS(HR=0.430,95%CI:0.325-0.569,p<0.001)。同时,据观察,TLS的检测结果与辅助化疗的给药显著相关(OR=1.505,95%CI:1.017-2.225,p=0.041).不仅如此,但与晚期N期(N=1,2和3)相比,早期N期(N=0)TLS检测显著升高的发生率更高(OR=1.604,95%CI:1.021-2.521,p=0.04).
结论:已观察到TLS检测的提高与扩展OS相关,DFS,和RFS在肺癌病例中的应用。这一发现表明TLS可能作为肺癌的有价值的预后生物标志物。
OBJECTIVE: The purpose of this meta-analysis was to examine the clinicopathological and prognostic significance of tertiary lymphocytic infiltrates in lung cancer.
METHODS: A systematic search was performed in many databases, including PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wangfangdate, and CBM, up until January 2024. We calculated the hazard ratio (HR), odds ratios (OR), and confidence interval (CI), and accomplished this meta-analysis with Stata 15 software.
RESULTS: 14 studies, including 3101 patients, were subjected to analysis. High TLS detection was associated with a longer OS (HR = 0.545, 95% CI: 0.359-0.827, p = 0.004), DFS (HR = 0.431, 95% CI: 0.350-0.531, p < 0.001), and RFS (HR = 0.430, 95% CI: 0.325-0.569, p < 0.001). Meanwhile, it was observed that a higher detection of TLS was significantly correlated with the administration of adjuvant chemotherapy (OR = 1.505, 95% CI: 1.017-2.225, p = 0.041). Not only that, but there was a higher occurrence of significantly elevated TLS detection in the early N stages (N = 0) compared to the advanced N stages (N = 1, 2, and 3) (OR = 1.604, 95% CI: 1.021-2.521, p = 0.04).
CONCLUSIONS: Elevated detection of TLS has been observed to be correlated with extended OS, DFS, and RFS in cases of lung cancer. This finding suggests that TLS could potentially serve as a valuable prognostic biomarker for lung cancer.